PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1927678
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1927678
The Water for Injection (WFI) Market size was valued at US$ 30,100.12 Million in 2024, expanding at a CAGR of 8.01% from 2025 to 2032.
The Water for Injection (WFI) Market includes highly purified water, which is used as a critical excipient and solvent in the production of parenteral drugs, vaccines, biologics, cell and gene therapies. Market growth is being driven by the rapid expansion of injectable pharmaceuticals and biologics, particularly in oncology, immunology, and vaccines. At the same time, there is a significant opportunity in the expansion of continuous manufacturing and modular pharmaceutical facilities, where on-demand WFI systems enable scalability, sustainability, and faster drug production. A notable trend is the increased use of membrane-based WFI generation technologies such as reverse osmosis and ultrafiltration, which provide greater energy efficiency and operational flexibility than traditional distillation. However, the market faces significant constraints in the form of high capital investment and stringent regulatory compliance requirements imposed by pharmacopeias and regulatory bodies.
Water for Injection (WFI) Market- Market Dynamics
Rising Investments in Drug Development are Expected To Drive Market Growth
The rising prevalence of various diseases, such as cancer and cardiovascular disease, is expected to drive the market during the forecast period. Water is an essential component of our tissues, accounting for approximately 70% of total body weight. Normal adult daily requirements range from two to three liters for insensible water loss through perspiration and urine production. When administered parenterally as a drug vehicle, sterile water for injection provides a source of water for parenteral fluid replenishment after a sufficient solute is added to achieve an osmolarity of 112 mol/liter. In addition, recent market opportunities have prompted service providers to make significant investments in advanced manufacturing facilities. For example, in January 2021, Thermo Fisher Scientific announced that it had acquired Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for $875 million. Fujifilm Corp. also invested approximately $928 million in Fujifilm Diosynth Biotechnologies, a CMO for biologic and advanced therapies. Increased investment in drug development leads to more research activities, which benefits the water for injection market.
The worldwide market is segmented on the basis of Packaging, Application, Product Type, Production Technology, End User, and Region.
Based on the application. The formulated parental drugs segment has a sizable market. Increased demand for parenteral drugs such as vaccines, insulin, and monoclonal antibodies is driving up the demand for injection water. Water for injection is critical for preserving the integrity and potency of parenteral drugs because it serves as a solvent and diluent for pharmaceutical ingredient activities. Parenteral drug formulation necessitates the use of high-quality injectable water. Advances in distillation and membrane-based purification technologies to improve the efficiency of injection water are gaining popularity in parenteral drug formulation. Furthermore, the increased demand for biopharmaceuticals, biosimilars, and biologics increases the need for water in injection formulations of parental drugs. In January 2025, NVIDIA partnered with Innophore's partnered artificial intelligence (AI)-driven for launching the CavitOmiX drug safety screening platform.
The pharmaceutical and biotechnology companies' segment is expected to drive market growth over the forecast period. The WFI is critical for drug formulation and other activities in pharmaceutical and biotechnology companies. According to the European Medicines Agency's 2020 data report, the European Pharmacopoeia established quality standards for various types of water used in pharmaceuticals, such as purified water, water for injections (WFI), and water for extract preparation. Many sterile medicinal products contain WFl, including biologics, parenteral, haemodiafiltration solutions, peritoneal dialysis solutions, and irrigation solutions. In addition, in 2020, the Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) agreed that the monoglaph mentioned in The International Pharmacopoeia (Water for injections) and the World Health Organization guideline good manufacturing practices include using WFI water for pharmaceuticals.
Furthermore, pharmaceutical companies perform a wide range of activities, including drug formulation. For instance, in the manufacturing process of injectable products, such as diluting or dissolving drug substances or preparations during parenteral product manufacturing, as well as the production of water for injection preparation. Bulk WFI can be used for the end of the cleaning of equipment that comes into contact with injectable products and a final rinse to ensure that no subsequent thermal or chemical deproteinization process is used.
Water for Injection (WFI) Market- Geographical Insights
North America commands the global market for water for injection, with an estimated 39.3% share in 2025. This is aided by a well-trained healthcare workforce and significant investment in pharmaceutical manufacturing infrastructure. The presence of major regulatory agencies, such as the U.S. FDA, ensures strict quality and purity standards for WFI products, boosting market trust. In September 2023, Actylis, a global leader in vital raw materials and performance ingredients for life sciences, has announced the implementation of a new cMP Water for Injection (WFI) generation, storage, and distribution system at its Baie d'Urfe facility in Montreal, Canada. The new system, which meets ISO 14644-1 Class 7 clean environment standards, is intended to meet USP and PhEur/BP specifications for water injection purposes.
United States Water for Injection (WFI) Market- Country Insights
The US water for injection market is very advanced, with a focus on innovation and compliance. Pharmaceutical behemoths such as Pfizer, Merck, and Baxter International not only dominate the domestic market, but also set global standards with their best manufacturing practices. The country's stringent regulations ensure a constant demand for high-quality purified water for injection formulations.
In June 2024, Xylem, a global leader in water technology solutions, introduced its MemEN water generation solution, which is intended to address the challenges of traditional pharmaceutical purification methods. The MemEN solution provides consistent purified water (PW) and water for injection (WFI), allowing pharmaceutical companies to reduce time to market while adhering to Global Pharmacopeia Standards.
The Water for Injection (WFI) Market is competitive, with a mix of global pharmaceutical manufacturers and specialized bioprocessing solution providers emphasizing product quality, regulatory compliance, and purification technology expertise. Key players compete by providing validated WFI systems, annual supply services, and end-to-end quality assurance to meet strict pharmacopeial standards. Companies differentiate themselves through technological innovation, global service networks, and collaborations with contract manufacturing organizations (CMOs) for biologics, vaccines, and sterile drug production. Danaher Corporation (Cytiva), known for bioprocessing and purification solutions; Merck KGaA, which provides comprehensive laboratory and water purification technologies; Veltek Associates, Inc., specializing in sterile reagents and water quality oversight; and Eurocrit Labs International, offering analytical testing services for WFI quality compliance. Other notable contributors, such as SteriCare Solutions and Rocky Mountain Biologicals, enhance competitive dynamics by meeting niche purification and biotech supply needs.
In January 2025, UK Dredging unveiled the UKD Seadragon, a water injection dredger, at Damen Shipyards. The cutting-edge vessel is based on the Shoalbuster 2711 design and takes an innovative approach to water injection dredging, resulting in exceptional efficiency and flexibility.
In November 2024, Veolia Water Technologies began offering mobile water services to the pharmaceutical, cosmetics, and life sciences industries throughout Europe. This service provides dependable, consistent, and long-term solutions for manufacturing, cleaning, and complex liquid waste treatment for compliant offsite management.